FDA Recall Terminated

VistaSolution, physiological signal transmitter. A software graphical user interface for use by healthcare professionals to display physiological data collected by the wireless remote monitoring system in healthcare settings. This is a secondary, adjunct patient monitor and is not intended to replace existing standard-of-care patient monitoring.

Recall: Z-2537-2020 · Initiated May 21, 2020

Recall

Recall Number
Z-2537-2020
Event Number
85802
Firm
Vitalconnect Inc.
FEI Number
3010830833
Product Code
DRG
Status
Terminated
Root Cause
Software Design Change
Initiated
May 21, 2020
Posted
July 10, 2020
Terminated
May 13, 2021
Address
224 Airport Pkwy, Ste 300, San Jose, CA, 95110-1022

Description

VistaSolution, physiological signal transmitter. A software graphical user interface for use by healthcare professionals to display physiological data collected by the wireless remote monitoring system in healthcare settings. This is a secondary, adjunct patient monitor and is not intended to replace existing standard-of-care patient monitoring.

Reason

A healthcare provider (HCP) noticed a patient had a lowered historic SpO2 reading that the software should have triggered a notification to the care team, but no notification was found. A software defect was encountered causing the lack of notification. The defect could result in exposing a patient to potential hypoxia for a short window of time. The firm is correcting the software to bring the performance back into compliance with specifications.

Action

On May 21, 2020, the firm sent a "Urgent: Medical Device Recall" notification to all affected customers via E-mail and mail. The letter stated, that the third party Sp02 continuous device notifications may not indicate an alert as intended. Therefore, the health care provider may not be notified to check the patient. Potential Hazards: A patient may have hypoxia and the designated health care provider may not be notified. The firm will be turning off the ability to set custom notifications containing continuous SP02 until the issue is resolved. The firm tells customers to monitor the patients for SPO2, as if the patients are not connected to the recalled device. The customers are informed to acknowledge the receipt of this notification by E-mail or via mail to the firm, email to: [email protected] and if any questions, then contact: Tony Wilder at phone: (408) 963-4600 or [email protected]

Distribution

U.S. Nationwide distribution including in the states of NJ, NY, VA, OUS: None

Quantity

7